Q-omics provides the consensus-scored MIDN profile across patient tissues and cancer cell-line models. MIDN expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, MIDN is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, MIDN RNA expression shows 18,175 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, KICH, and ACC as cancer lineages where MIDN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIDN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIDN survival associations across molecular data types. MIDN RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIDN RNA expression–survival associations across cancer types. High MIDN expression shows unfavorable associations in LUAD, MESO and READ, but favorable associations in SCLC, ESCA and THCA. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SCLC as the clearest survival context for MIDN RNA expression.
This table summarizes MIDN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MIDN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIDN shows lower tumor expression in KICH, BLCA and LUSC and higher tumor expression in BRCA, CHOL and STAD. The KICH box plot shows higher MIDN RNA expression in normal versus tumor tissue (log2 FC = −2.640, t-test p < 0.001).
This table shows molecular features associated with MIDN in patient tissues and cancer cell lines. In patient samples, MIDN shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MIDN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
